Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 4.1% After Analyst DowngradeMarket Beat·23 hours agoGLUE+4.94%
Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its GoalSimplywall·Aug 1 at 02:13 AMNVO+0.50%GLUE+4.94%
Buy Rating Maintained on Monte Rosa as Diversified Degrader Pipeline and Novartis Partnership Offset ZEUS Cardiovascular SetbackTip Ranks·Jul 31 at 01:45 PMGLUE+4.94%NVS+0.15%
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipelinebusinessinsider·Jul 31 at 01:16 PMBIOA-3.62%GLUE+4.94%
Monte Rosa CSO Sharon Townson disposes of common shares worth $140,297.2PUBT·Jul 7 at 03:42 PMGLUE+4.94%
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9% - Should You Buy?Market Beat·Jul 7 at 01:40 PMGLUE+4.94%BAC+1.35%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by BrokeragesMarket Beat·Jul 5 at 07:29 AMGLUE+4.94%
Monte Rosa Therapeutics grants inducement awards to new hires, including options for 18,025 shares at $24.02PUBT·Jul 2 at 03:01 PMGLUE+4.94%
Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) StockMarket Beat·Jul 1 at 04:07 PMGLUE+4.94%
Monte Rosa Therapeutics director Anthony M. Manning disposes of 10,000 common shares worth $231,100PUBT·Jun 30 at 03:06 PMGLUE+4.94%
Monte Rosa Therapeutics (GLUE) Joins Russell Growth Indexes, Is The Upside Already Priced In?Simplywall·Jun 30 at 03:06 AMGLUE+4.94%
Monte Rosa Therapeutics CSO Sharon Townson disposes of 3,000 common shares for $60,000PUBT·Jun 25 at 03:05 PMGLUE+4.94%
